Major Depression Clinical Trial
Official title:
Efficacy of Bilateral Dorsolateral Prefrontal Theta-burst Stimulation in Elderly Refractory Depression: a Randomized Sham-controlled Study
The study aim to examine the effect of Thea-burst stimulation over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers.
Thea-burst stimulation (TBS) is a novel form of rTMS, providing greater modulation effect on neural activity. So far, no study was conducted to use TBS as treatment in LLD. Therefore, we aim to examine the effect of TBS over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers. The study used a two-arm, parallel, double-blind, randomized, and sham-controlled design. We plan to enroll sixty patients with LLD, thirty for active intervention and thirty for sham-controlled group. An Magstim Rapid2 stimulator with eight-figure coil was used for stimulation. Location of brain area are based on bilateral DLPFC. 3-pulse 50-Hz bursts was given every 200ms (at 5 Hz) and an intensity of 80% active motor threshold was settled. We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses). Each patient received daily stimulation for two weeks with total ten sessions. The primary outcomes were change of depression severity including response and remission rate. Secondary outcome were biomarkers related to depression. Assessments were administered at baseline, immediately after 5 and 10 sessions of stimulation, and 3 months after the completion of stimulation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
| Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
| Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
| Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
| Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
| Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
| Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
| Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
| Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
| Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
| Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
| Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
| Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
| Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
| Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
| Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
| Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
| Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
| Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
| Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 |